Antimicrobial activity of lactoferrin and lactoferrin derived peptides

Antimicrobial Activity of Lactoferrin and Lactoferrin Derived Peptides

Volumn , Issue , 2009, Pages 1-102

  Jenssen, Håvard ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861500039     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (425)

1. Aboudy, Y., E. Mendelson, I. Shalit, R. Bessalle, and M. Fridkin. 1994. Activity of two synthetic amphiphilic peptides and magainin-2 against herpes simplex virus types 1 and 2. Int J Pept Protein Res 43:573-82.
2. Aguilera, O., H. Ostolaza, L. M. Quiros, and J. F. Fierro. 1999. Permeabilizing action of an antimicrobial lactoferricin-derived peptide on bacterial and artificial membranes. FEBS Lett 462:273-7.
3. Almaas, H., H. Holm, T. Langsrud, R. Flengsrud, and G. E. Vegarud. 2006. In vitro studies of the digestion of caprine whey proteins by human gastric and duodenal juice and the effects on selected microorganisms. Br J Nutr 96:562-9.
4. Andersen, J. H. 2004. Technology evaluation: rh lactoferrin, Agennix. Curr Opin Mol Ther 6:344-9.
5. Andersen, J. H., H. Jenssen, and T. J. Gutteberg. 2003. Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. Antiviral Res 58:209-15.
6. Andersen, J. H., H. Jenssen, K. Sandvik, and T. J. Gutteberg. 2004. Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparan sulphate at the cell surface. J Med Virol 74:262-71.
7. Andersen, J. H., S. A. Osbakk, L. H. Vorland, T. Traavik, and T. J. Gutteberg. 2001. Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts. Antiviral Res 51:141-9.
8. Anderson, B. F., H. M. Baker, E. J. Dodson, G. E. Norris, S. V. Rumball, J. M. Waters, and E. N. Baker. 1987. Structure of human lactoferrin at 3.2-A resolution. Proc Natl Acad Sci U S A 84:1769-73.
9. Anderson, J. E., M. M. Hobbs, G. D. Biswas, and P. F. Sparling. 2003. Opposing selective forces for expression of the gonococcal lactoferrin receptor. Mol Microbiol 48:1325-37.
10. Andersson, E., V. Rydengard, A. Sonesson, M. Morgelin, L. Bjorck, and A. Schmidtchen. 2004. Antimicrobial activities of heparin-binding peptides. Eur J Biochem 271:1219-26.
11. Andreu, D., and L. Rivas. 1998. Animal antimicrobial peptides: an overview. Biopolymers 47:415-33.
12. Appelmelk, B. J., Y. Q. An, M. Geerts, B. G. Thijs, H. A. de Boer, D. M. MacLaren, J. de Graaff, and J. H. Nuijens. 1994. Lactoferrin is a lipid Abinding protein. Infect Immun 62:2628-32.
13. Argyris, E. G., E. Acheampong, G. Nunnari, M. Mukhtar, K. J. Williams, and R. J. Pomerantz. 2003. Human immunodeficiency virus type 1 enters primary human brain microvascular endothelial cells by a mechanism involving cell surface proteoglycans independent of lipid rafts. J Virol 77:12140-51.
14. Arnold, D., A. M. Di Biase, M. Marchetti, A. Pietrantoni, P. Valenti, L. Seganti, and F. Superti. 2002. Antiadenovirus activity of milk proteins:lactoferrin prevents viral infection. Antiviral Res 53:153-8.
15. Arnold, R. R., M. Brewer, and J. J. Gauthier. 1980. Bactericidal activity of human lactoferrin: sensitivity of a variety of microorganisms. Infect Immun 28:893-8.
16. Arnold, R. R., M. F. Cole, and J. R. McGhee. 1977. A bactericidal effect for human lactoferrin. Science 197:263-5.
17. Arnold, R. R., J. E. Russell, W. J. Champion, and J. J. Gauthier. 1981. Bactericidal activity of human lactoferrin: influence of physical conditions and metabolic state of the target microorganism. Infect Immun 32:655-60.
18. Ashida, K., H. Sasaki, Y. A. Suzuki, and B. Lonnerdal. 2004. Cellular internalization of lactoferrin in intestinal epithelial cells. Biometals 17:311-5.
19. Baggiolini, M., C. De Duve, P. L. Masson, and J. F. Heremans. 1970. Association of lactoferrin with specific granules in rabbit heterophil leukocytes. J Exp Med 131:559-70.
20. Baker, E. N., B. F. Anderson, H. M. Baker, C. L. Day, M. Haridas, G. E. Norris, S. V. Rumball, C. A. Smith, and D. H. Thomas. 1994. Threedimensional structure of lactoferrin in various functional states. Adv Exp Med Biol 357:1-12.
21. Baker, E. N., H. M. Baker, and R. D. Kidd. 2002. Lactoferrin and transferrin: functional variations on a common structural framework. Biochem Cell Biol 80:27-34.
22. Baker, H. M., and E. N. Baker. 2004. Lactoferrin and iron: structural and dynamic aspects of binding and release. Biometals 17:209-16.
23. Baker, M. A., W. L. Maloy, M. Zasloff, and L. S. Jacob. 1993. Anticancer efficacy of Magainin2 and analogue peptides. Cancer Res 53:3052-7.
24. Barth, H., C. Schafer, M. I. Adah, F. Zhang, R. J. Linhardt, H. Toyoda, A. Kinoshita-Toyoda, T. Toida, T. H. Van Kuppevelt, E. Depla, F. Von Weizsacker, H. E. Blum, and T. F. Baumert. 2003. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 278:41003-12.
25. Beaumont, S. L., D. J. Maggs, and H. E. Clarke. 2003. Effects of bovine lactoferrin on in vitro replication of feline herpesvirus. Vet Ophthalmol 6:245-50.
26. Belaid, A., M. Aouni, R. Khelifa, A. Trabelsi, M. Jemmali, and K. Hani. 2002. In vitro antiviral activity of dermaseptins against herpes simplex virus type 1. J Med Virol 66:229-34.
27. Beljaars, L., H. I. Bakker, B. W. van der Strate, C. Smit, A. M. Duijvestijn, D. K. Meijer, and G. Molema. 2002. The antiviral protein human lactoferrin is distributed in the body to cytomegalovirus (CMV) infection-prone cells and tissues. Pharm Res 19:54-62.
28. Beljaars, L., B. W. van der Strate, H. I. Bakker, C. Reker-Smit, A. M. van Loenen-Weemaes, F. C. Wiegmans, M. C. Harmsen, G. Molema, and D. K. Meijer. 2004. Inhibition of cytomegalovirus infection by lactoferrin in vitro and in vivo. Antiviral Res 63:197-208.
29. Bellamy, W., M. Takase, H. Wakabayashi, K. Kawase, and M. Tomita. 1992. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J Appl Bacteriol 73:472-9.
30. Bellamy, W., M. Takase, K. Yamauchi, H. Wakabayashi, K. Kawase, and M. Tomita. 1992. Identification of the bactericidal domain of lactoferrin. Biochim Biophys Acta 1121:130-6.
31. Bellamy, W., H. Wakabayashi, M. Takase, K. Kawase, S. Shimamura, and M. Tomita. 1993. Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Med Microbiol Immunol (Berl) 182:97-105.
32. Bellamy, W. R., H. Wakabayashi, M. Takase, K. Kawase, S. Shimamura, and M. Tomita. 1993. Role of cell-binding in the antibacterial mechanism of lactoferricin B. J Appl Bacteriol 75:478-84.
33. Benne, C. A., C. A. Kraaijeveld, J. A. van Strijp, E. Brouwer, M. Harmsen, J. Verhoef, L. M. van Golde, and J. F. van Iwaarden. 1995. Interactions of surfactant protein A with influenza A viruses: binding and neutralization. J Infect Dis 171:335-41.
34. Berkhout, B., R. Floris, I. Recio, and S. Visser. 2004. The antiviral activity of the milk protein lactoferrin against the human immunodeficiency virus type 1. Biometals 17:291-4.
35. Berkhout, B., J. L. van Wamel, L. Beljaars, D. K. Meijer, S. Visser, and R. Floris. 2002. Characterization of the anti-HIV effects of native lactoferrin and other milk proteins and protein-derived peptides. Antiviral Res 55:341-55.
36. Berlutti, F., C. Morea, A. Battistoni, S. Sarli, P. Cipriani, F. Superti, M. G. Ammendolia, and P. Valenti. 2005. Iron availability influences aggregation, biofilm, adhesion and invasion of Pseudomonas aeruginosa and Burkholderia cenocepacia. Int J Immunopathol Pharmacol 18:661-70.
37. Bernfield, M., R. Kokenyesi, M. Kato, M. T. Hinkes, J. Spring, R. L. Gallo, and E. J. Lose. 1992. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 8:365-93.
38. Birgens, H. S., N. E. Hansen, H. Karle, and L. O. Kristensen. 1983. Receptor binding of lactoferrin by human monocytes. Br J Haematol 54:383-91.
39. Blocker, A., P. Gounon, E. Larquet, K. Niebuhr, V. Cabiaux, C. Parsot, and P. Sansonetti. 1999. The tripartite type III secreton of Shigella flexneri inserts IpaB and IpaC into host membranes. J Cell Biol 147:683-93.
40. Boman, H. G. 1995. Peptide antibiotics and their role in innate immunity. Annu Rev Immunol 13:61-92.
41. Boman, H. G., B. Agerberth, and A. Boman. 1993. Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine. Infect Immun 61:2978-84.
42. Bortner, C. A., R. R. Arnold, and R. D. Miller. 1989. Bactericidal effect of lactoferrin on Legionella pneumophila: effect of the physiological state of the organism. Can J Microbiol 35:1048-51.
43. Bousarghin, L., A. Touze, A. L. Combita-Rojas, and P. Coursaget. 2003. Positively charged sequences of human papillomavirus type 16 capsid proteins are sufficient to mediate gene transfer into target cells via the heparan sulfate receptor. J Gen Virol 84:157-64.
44. Bowdish, D. M., D. J. Davidson, and R. E. W. Hancock. 2005. A reevaluation of the role of host defence peptides in mammalian immunity. Curr Protein Pept Sci 6:35-51.
45. Bowdish, D. M., D. J. Davidson, D. P. Speert, and R. E. W. Hancock. 2004. The human cationic peptide LL-37 induces activation of the extracellular signal-regulated kinase and p38 kinase pathways in primary human monocytes. J Immunol 172:3758-65.
46. Brandenburg, K., G. Jurgens, M. Muller, S. Fukuoka, and M. H. Koch. 2001. Biophysical characterization of lipopolysaccharide and lipid A inactivation by lactoferrin. Biol Chem 382:1215-25.
47. Brantl, V., H. Teschemacher, A. Henschen, and F. Lottspeich. 1979. Novel opioid peptides derived from casein (beta-casomorphins). I. Isolation from bovine casein peptone. Hoppe Seylers Z Physiol Chem 360:1211-6.
48. Brines, R. D., and J. H. Brock. 1983. The effect of trypsin and chymotrypsin on the in vitro antimicrobial and iron-binding properties of lactoferrin in human milk and bovine colostrum. Unusual resistance of human apolactoferrin to proteolytic digestion. Biochim Biophys Acta 759:229-35.
49. Britton, J. R., and O. Koldovsky. 1989. Gastric luminal digestion of lactoferrin and transferrin by preterm infants. Early Hum Dev 19:127-35.
50. Brock, J. 1995. Lactoferrin: a multifunctional immunoregulatory protein? Immunol Today 16:417-9.
51. Brock, J. H. 2002. The physiology of lactoferrin. Biochem Cell Biol 80:1-6.
52. Brogan, T. D., H. C. Ryley, L. Neale, and J. Yassa. 1975. Soluble proteins of bronchopulmonary secretions from patients with cystic fibrosis, asthma, and bronchitis. Thorax 30:72-9.
53. Brogden, K. A. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 3:238-50.
54. Bullen, J. J., H. J. Rogers, and L. Leigh. 1972. Iron-binding proteins in milk and resistance to Escherichia coli infection in infants. Br Med J 1:69-75.
55. Buttner, D., and U. Bonas. 2002. Port of entry--the type III secretion translocon. Trends Microbiol 10:186-92.
56. Camejo, E. H., B. Rosengren, G. Camejo, P. Sartipy, G. Fager, and G. Bondjers. 1995. Interferon gamma binds to extracellular matrix chondroitinsulfate proteoglycans, thus enhancing its cellular response. Arterioscler Thromb Vasc Biol 15:1456-65.
57. Cappelli, G., S. Paladini, and A. D’Agata. 1999. Tumor markers in the diagnosis of pancreatic cancer. Tumori 85:S19-21.
58. Castle, M., A. Nazarian, S. S. Yi, and P. Tempst. 1999. Lethal effects of apidaecin on Escherichia coli involve sequential molecular interactions with diverse targets. J Biol Chem 274:32555-64.
59. Chan, Y. R., and R. L. Gallo. 1998. PR-39, a syndecan-inducing antimicrobial peptide, binds and affects p130(Cas). J Biol Chem 273:28978-85.
60. Chang, T. L., J. Vargas, Jr., A. DelPortillo, and M. E. Klotman. 2005. Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest 115:765-73.
61. Chapple, D. S., R. Hussain, C. L. Joannou, R. E. W. Hancock, E. Odell, R. W. Evans, and G. Siligardi. 2004. Structure and association of human lactoferrin peptides with Escherichia coli lipopolysaccharide. Antimicrob Agents Chemother 48:2190-8.
62. Chapple, D. S., D. J. Mason, C. L. Joannou, E. W. Odell, V. Gant, and R. W. Evans. 1998. Structure-function relationship of antibacterial synthetic peptides homologous to a helical surface region on human lactoferrin against Escherichia coli serotype O111. Infect Immun 66:2434-40.
63. Chen, H. L., Y. W. Lai, C. C. Yen, Y. Y. Lin, C. Y. Lu, S. H. Yang, T. C. Tsai, Y. J. Lin, C. W. Lin, and C. M. Chen. 2004. Production of recombinant porcine lactoferrin exhibiting antibacterial activity in methylotrophic yeast, Pichia pastoris. J Mol Microbiol Biotechnol 8:141-9.
64. Chen, H. L., C. C. Yen, C. Y. Lu, C. H. Yu, and C. M. Chen. 2006. Synthetic porcine lactoferricin with a 20-residue peptide exhibits antimicrobial activity against Escherichia coli, Staphylococcus aureus, and Candida albicans. J Agric Food Chem 54:3277-82.
65. Chen, H. M., W. Wang, D. Smith, and S. C. Chan. 1997. Effects of the antibacterial peptide cecropin B and its analogs, cecropins B-1 and B-2, on liposomes, bacteria, and cancer cells. Biochim Biophys Acta 1336:171-9.
66. Chertov, O., D. F. Michiel, L. Xu, J. M. Wang, K. Tani, W. J. Murphy, D. L. Longo, D. D. Taub, and J. J. Oppenheim. 1996. Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem 271:2935-40.
67. Cheshenko, N., and B. C. Herold. 2002. Glycoprotein B plays a predominant role in mediating herpes simplex virus type 2 attachment and is required for entry and cell-to-cell spread. J Gen Virol 83:2247-55.
68. Cirioni, O., A. Giacometti, F. Barchiesi, and G. Scalise. 2000. Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline. J Antimicrob Chemother 46:577-82.
69. Combita, A. L., A. Touze, L. Bousarghin, P. Y. Sizaret, N. Munoz, and P. Coursaget. 2001. Gene transfer using human papillomavirus pseudovirions varies according to virus genotype and requires cell surface heparan sulfate. FEMS Microbiol Lett 204:183-8.
70. Conneely, O. M. 2001. Antiinflammatory activities of lactoferrin. J Am Coll Nutr 20:389S-395S; discussion 396S-397S.
71. Crouch, S. P., K. J. Slater, and J. Fletcher. 1992. Regulation of cytokine release from mononuclear cells by the iron-binding protein lactoferrin. Blood 80:235-40.
72. Cruciani, R. A., J. L. Barker, M. Zasloff, H. C. Chen, and O. Colamonici. 1991. Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation. Proc Natl Acad Sci U S A 88:3792-6.
73. Daher, K. A., M. E. Selsted, and R. I. Lehrer. 1986. Direct inactivation of viruses by human granulocyte defensins. J Virol 60:1068-74.
74. Dalmastri, C., P. Valenti, P. Visca, P. Vittorioso, and N. Orsi. 1988. Enhanced antimicrobial activity of lactoferrin by binding to the bacterial surface. Microbiologica 11:225-30.
75. Dathe, M., and T. Wieprecht. 1999. Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells. Biochim Biophys Acta 1462:71-87.
76. Davidson, D. J., A. J. Currie, G. S. Reid, D. M. Bowdish, K. L. MacDonald, R. C. Ma, R. E. W. Hancock, and D. P. Speert. 2004. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol 172:1146-56.
77. Davidson, L. A., and B. Lonnerdal. 1986. Isolation and characterization of rhesus monkey milk lactoferrin. Pediatr Res 20:197-201.
78. Davies, J. S., C. Enjalbal, C. Wise, G. Jones, and B. K. Handa. 1994. Further studies on cyclic RGD analogues. Biochem Soc Trans 22:1049-52.
79. De Lucca, A. J., and T. J. Walsh. 1999. Antifungal peptides: novel therapeutic compounds against emerging pathogens. Antimicrob Agents Chemother 43:1-11.
80. Dhaenens, L., F. Szczebara, and M. O. Husson. 1997. Identification, characterization, and immunogenicity of the lactoferrin-binding protein from Helicobacter pylori. Infect Immun 65:514-8.
81. Di Biase, A. M., A. Pietrantoni, A. Tinari, R. Siciliano, P. Valenti, G. Antonini, L. Seganti, and F. Superti. 2003. Heparin-interacting sites of bovine lactoferrin are involved in anti-adenovirus activity. J Med Virol 69:495-502.
82. DiGabriele, A. D., I. Lax, D. I. Chen, C. M. Svahn, M. Jaye, J. Schlessinger, and W. A. Hendrickson. 1998. Structure of a heparin-linked biologically active dimer of fibroblast growth factor. Nature 393:812-7.
83. Dionysius, D. A., and J. M. Milne. 1997. Antibacterial peptides of bovine lactoferrin: purification and characterization. J Dairy Sci 80:667-74.
84. Drobni, P., N. Mistry, N. McMillan, and M. Evander. 2003. Carboxyfluorescein diacetate, succinimidyl ester labeled papillomavirus virus-like particles fluoresce after internalization and interact with heparan sulfate for binding and entry. Virology 310:163-72.
85. Drobni, P., J. Naslund, and M. Evander. 2004. Lactoferrin inhibits human papillomavirus binding and uptake in vitro. Antiviral Res 64:63-8.
86. Ehrenstein, G., and H. Lecar. 1977. Electrically gated ionic channels in lipid bilayers. Q Rev Biophys 10:1-34.
87. Ekins, A., A. G. Khan, S. R. Shouldice, and A. B. Schryvers. 2004. Lactoferrin receptors in gram-negative bacteria: insights into the iron acquisition process. Biometals 17:235-43.
88. Elass-Rochard, E., A. Roseanu, D. Legrand, M. Trif, V. Salmon, C. Motas, J. Montreuil, and G. Spik. 1995. Lactoferrin-lipopolysaccharide interaction:involvement of the 28-34 loop region of human lactoferrin in the highaffinity binding to Escherichia coli 055B5 lipopolysaccharide. Biochem J 312 (Pt 3):839-45.
89. Eliassen, L. T., G. Berge, A. Leknessund, M. Wikman, I. Lindin, C. Lokke, F. Ponthan, J. I. Johnsen, B. Sveinbjornsson, P. Kogner, T. Flaegstad, and O. Rekdal. 2006. The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. Int J Cancer 119:493-500.
90. Eliassen, L. T., G. Berge, B. Sveinbjornsson, J. S. Svendsen, L. H. Vorland, and O. Rekdal. 2002. Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res 22:2703-10.
91. Ellerby, H. M., W. Arap, L. M. Ellerby, R. Kain, R. Andrusiak, G. D. Rio, S. Krajewski, C. R. Lombardo, R. Rao, E. Ruoslahti, D. E. Bredesen, and R. Pasqualini. 1999. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5:1032-8.
92. Ellison, R. T., 3rd, and T. J. Giehl. 1991. Killing of gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest 88:1080-91.
93. Ellison, R. T., 3rd, T. J. Giehl, and F. M. LaForce. 1988. Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin. Infect Immun 56:2774-81.
94. Ellison, R. T., 3rd, F. M. LaForce, T. J. Giehl, D. S. Boose, and B. E. Dunn. 1990. Lactoferrin and transferrin damage of the gram-negative outer membrane is modulated by Ca2+ and Mg2+. J Gen Microbiol 136:1437-46.
95. Elsbach, P. 2003. What is the real role of antimicrobial polypeptides that can mediate several other inflammatory responses? J Clin Invest 111:1643-5.
96. Epand, R. M., and H. J. Vogel. 1999. Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta 1462:11-28.
97. Erdei, J., A. Forsgren, and A. S. Naidu. 1994. Lactoferrin binds to porins OmpF and OmpC in Escherichia coli. Infect Immun 62:1236-40.
98. Esteban, M. A., A. Rodriguez, A. Cuesta, and J. Meseguer. 2005. Effects of lactoferrin on non-specific immune responses of gilthead seabream (Sparus auratus L.). Fish Shellfish Immunol 18:109-24.
99. Evander, M., I. H. Frazer, E. Payne, Y. M. Qi, K. Hengst, and N. A. McMillan. 1997. Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J Virol 71:2449-56.
100. Faber, C., H. P. Stallmann, D. M. Lyaruu, U. Joosten, C. von Eiff, A. van Nieuw Amerongen, and P. I. Wuisman. 2005. Comparable efficacies of the antimicrobial peptide human lactoferrin 1-11 and gentamicin in a chronic methicillin-resistant Staphylococcus aureus osteomyelitis model. Antimicrob Agents Chemother 49:2438-44.
101. Farnaud, S., and R. W. Evans. 2003. Lactoferrin--a multifunctional protein with antimicrobial properties. Mol Immunol 40:395-405.
102. Feldman, M. F., and G. R. Cornelis. 2003. The multitalented type III chaperones: all you can do with 15 kDa. FEMS Microbiol Lett 219:151-8.
103. Feng, X. J., J. H. Wang, A. S. Shan, D. Teng, Y. L. Yang, Y. Yao, G. P. Yang, Y. C. Shao, S. Liu, and F. Zhang. 2006. Fusion expression of bovine lactoferricin in Escherichia coli. Protein Expr Purif 47:110-7.
104. Florisa, R., I. Recio, B. Berkhout, and S. Visser. 2003. Antibacterial and antiviral effects of milk proteins and derivatives thereof. Curr Pharm Des 9:1257-75.
105. Ford, M. J. 2001. Molecular evolution of transferrin: evidence for positive selection in salmonids. Mol Biol Evol 18:639-47.
106. Friedrich, C. L., D. Moyles, T. J. Beveridge, and R. E. W. Hancock. 2000. Antibacterial action of structurally diverse cationic peptides on grampositive bacteria. Antimicrob Agents Chemother 44:2086-92.
107. Friedrich, C. L., A. Rozek, A. Patrzykat, and R. E. W. Hancock. 2001. Structure and mechanism of action of an indolicidin peptide derivative with improved activity against gram-positive bacteria. J Biol Chem 276:24015-22.
108. Frishman, W. H., B. Burns, B. Atac, N. Alturk, B. Altajar, and K. Lerrick. 1995. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J 130:877-92.
109. Fromm, J. R., R. E. Hileman, E. E. Caldwell, J. M. Weiler, and R. J. Linhardt. 1995. Differences in the interaction of heparin with arginine and lysine and the importance of these basic amino acids in the binding of heparin to acidic fibroblast growth factor. Arch Biochem Biophys 323:279-87.
110. Fuchs, S. M., and R. T. Raines. 2004. Pathway for polyarginine entry into mammalian cells. Biochemistry 43:2438-44.
111. Fujihara, T., and K. Hayashi. 1995. Lactoferrin inhibits herpes simplex virus type-1 (HSV-1) infection to mouse cornea. Arch Virol 140:1469-72.
112. Fujimura, M., M. Ideguchi, Y. Minami, K. Watanabe, and K. Tadera. 2004. Purification, characterization, and sequencing of novel antimicrobial peptides, Tu-AMP 1 and Tu-AMP 2, from bulbs of tulip (Tulipa gesneriana L.). Biosci Biotechnol Biochem 68:571-7.
113. Furlong, S. J., J. S. Mader, and D. W. Hoskin. 2006. Lactoferricin-induced apoptosis in estrogen-nonresponsive MDA-MB-435 breast cancer cells is enhanced by C6 ceramide or tamoxifen. Oncol Rep 15:1385-90.
114. Futaki, S. 2002. Arginine-rich peptides: potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms. Int J Pharm 245:1-7.
115. Futaki, S., I. Nakase, T. Suzuki, Z. Youjun, and Y. Sugiura. 2002. Translocation of branched-chain arginine peptides through cell membranes:flexibility in the spatial disposition of positive charges in membranepermeable peptides. Biochemistry 41:7925-30.
116. Gahr, M., C. P. Speer, B. Damerau, and G. Sawatzki. 1991. Influence of lactoferrin on the function of human polymorphonuclear leukocytes and monocytes. J Leukoc Biol 49:427-33.
117. Ganz, T. 2005. Defensins and other antimicrobial peptides: a historical perspective and an update. Comb Chem High Throughput Screen 8:209-17.
118. Giansanti, F., M. T. Massucci, M. F. Giardi, F. Nozza, E. Pulsinelli, C. Nicolini, D. Botti, and G. Antonini. 2005. Antiviral activity of ovotransferrin derived peptides. Biochem Biophys Res Commun 331:69-73.
119. Gifford, J. L., H. N. Hunter, and H. J. Vogel. 2005. Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol Life Sci 62:2588-98.
120. Giroglou, T., L. Florin, F. Schafer, R. E. Streeck, and M. Sapp. 2001. Human papillomavirus infection requires cell surface heparan sulfate. J Virol 75:1565-70.
121. Goldman, R. C., and A. Branstrom. 1999. Targeting cell wall synthesis and assembly in microbes: similarities and contrasts between bacteria and fungi. Curr Pharm Des 5:473-501.
122. Gomez, H. F., T. J. Ochoa, L. G. Carlin, and T. G. Cleary. 2003. Human lactoferrin impairs virulence of Shigella flexneri. J Infect Dis 187:87-95.
123. Grossmann, J. G., M. Neu, E. Pantos, F. J. Schwab, R. W. Evans, E. Townes-Andrews, P. F. Lindley, H. Appel, W. G. Thies, and S. S. Hasnain. 1992. X-ray solution scattering reveals conformational changes upon iron uptake in lactoferrin, serum and ovo-transferrins. J Mol Biol 225:811-9.
124. Grover, M., O. Giouzeppos, R. D. Schnagl, and J. T. May. 1997. Effect of human milk prostaglandins and lactoferrin on respiratory syncytial virus and rotavirus. Acta Paediatr 86:315-6.
125. Hallock, K. J., D. K. Lee, and A. Ramamoorthy. 2003. MSI-78, an analogue of the magainin antimicrobial peptides, disrupts lipid bilayer structure via positive curvature strain. Biophys J 84:3052-60.
126. Hammerschmidt, S., G. Bethe, P. H. Remane, and G. S. Chhatwal. 1999. Identification of pneumococcal surface protein A as a lactoferrin-binding protein of Streptococcus pneumoniae. Infect Immun 67:1683-7.
127. Hancock, R. E. W. 2001. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 1:156-64.
128. Hancock, R. E. W., and D. S. Chapple. 1999. Peptide antibiotics. Antimicrob Agents Chemother 43:1317-23.
129. Hancock, R. E. W., and G. Diamond. 2000. The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol 8:402-10.
130. Hancock, R. E. W., and A. Patrzykat. 2002. Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. Curr Drug Targets Infect Disord 2:79-83.
131. Hancock, R. E. W., and A. Rozek. 2002. Role of membranes in the activities of antimicrobial cationic peptides. FEMS Microbiol Lett 206:143-9.
132. Hara, K., M. Ikeda, S. Saito, S. Matsumoto, K. Numata, N. Kato, K. Tanaka, and H. Sekihara. 2002. Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepatol Res 24:228.
133. Haridas, M., B. F. Anderson, H. M. Baker, G. E. Norris, and E. N. Baker. 1994. X-ray structural analysis of bovine lactoferrin at 2.5 A resolution. Adv Exp Med Biol 357:235-8.
134. Harmsen, M. C., P. J. Swart, M. P. de Bethune, R. Pauwels, E. De Clercq, T. H. The, and D. K. Meijer. 1995. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis 172:380-8.
135. Hasegawa, K., W. Motsuchi, S. Tanaka, and S. Dosako. 1994. Inhibition with lactoferrin of in vitro infection with human herpes virus. Jpn J Med Sci Biol 47:73-85.
136. Haug, B. E., M. L. Skar, and J. S. Svendsen. 2001. Bulky aromatic amino acids increase the antibacterial activity of 15-residue bovine lactoferricin derivatives. J Pept Sci 7:425-32.
137. Haukland, H. H., H. Ulvatne, K. Sandvik, and L. H. Vorland. 2001. The antimicrobial peptides lactoferricin B and magainin 2 cross over the bacterial cytoplasmic membrane and reside in the cytoplasm. FEBS Lett 508:389-93.
138. Haurum, J. S., S. Thiel, I. M. Jones, P. B. Fischer, S. B. Laursen, and J. C. Jensenius. 1993. Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. Aids 7:1307-13.
139. He, J., and P. Furmanski. 1995. Sequence specificity and transcriptional activation in the binding of lactoferrin to DNA. Nature 373:721-4.
140. He, K., S. J. Ludtke, D. L. Worcester, and H. W. Huang. 1996. Neutron scattering in the plane of membranes: structure of alamethicin pores. Biophys J 70:2659-66.
141. Hellberg, S., M. Sjostrom, B. Skagerberg, and S. Wold. 1987. Peptide quantitative structure-activity relationships, a multivariate approach. J Med Chem 30:1126-35.
142. Helmerhorst, E. J., R. F. Troxler, and F. G. Oppenheim. 2001. The human salivary peptide histatin 5 exerts its antifungal activity through the formation of reactive oxygen species. Proc Natl Acad Sci U S A 98:14637-42.
143. Hendrixson, D. R., J. Qiu, S. C. Shewry, D. L. Fink, S. Petty, E. N. Baker, A. G. Plaut, and J. W. St Geme, 3rd. 2003. Human milk lactoferrin is a serine protease that cleaves Haemophilus surface proteins at arginine-rich sites. Mol Microbiol 47:607-17.
144. Henschen, A., F. Lottspeich, V. Brantl, and H. Teschemacher. 1979. Novel opioid peptides derived from casein (beta-casomorphins). II. Structure of active components from bovine casein peptone. Hoppe Seylers Z Physiol Chem 360:1217-24.
145. Henzler Wildman, K. A., D. K. Lee, and A. Ramamoorthy. 2003. Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. Biochemistry 42:6545-58.
146. Herold, B. C., S. I. Gerber, B. J. Belval, A. M. Siston, and N. Shulman. 1996. Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry. J Virol 70:3461-9.
147. Herz, J., and D. K. Strickland. 2001. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 108:779-84.
148. Hileman, R. E., J. R. Fromm, J. M. Weiler, and R. J. Linhardt. 1998. Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays 20:156-67.
149. Hoek, K. S., J. M. Milne, P. A. Grieve, D. A. Dionysius, and R. Smith. 1997. Antibacterial activity in bovine lactoferrin-derived peptides. Antimicrob Agents Chemother 41:54-9.
150. Hoogewerf, A. J., G. S. Kuschert, A. E. Proudfoot, F. Borlat, I. Clark-Lewis, C. A. Power, and T. N. Wells. 1997. Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry 36:13570-8.
151. Hovanessian, A. G., F. Puvion-Dutilleul, S. Nisole, J. Svab, E. Perret, J. S. Deng, and B. Krust. 2000. The cell-surface-expressed nucleolin is associated with the actin cytoskeleton. Exp Cell Res 261:312-28.
152. Hsu, C. H., C. Chen, M. L. Jou, A. Y. Lee, Y. C. Lin, Y. P. Yu, W. T. Huang, and S. H. Wu. 2005. Structural and DNA-binding studies on the bovine antimicrobial peptide, indolicidin: evidence for multiple conformations involved in binding to membranes and DNA. Nucleic Acids Res 33:4053-64.
153. Huang, R. H., Y. Xiang, G. Z. Tu, Y. Zhang, and D. C. Wang. 2004. Solution structure of Eucommia antifungal peptide: a novel structural model distinct with a five-disulfide motif. Biochemistry 43:6005-12.
154. Hung, S. L., S. Srinivasan, H. M. Friedman, R. J. Eisenberg, and G. H. Cohen. 1992. Structural basis of C3b binding by glycoprotein C of herpes simplex virus. J Virol 66:4013-27.
155. Hunter, H. N., A. R. Demcoe, H. Jenssen, T. J. Gutteberg, and H. J. Vogel. 2005. Human lactoferricin is partially folded in aqueous solution and is better stabilized in a membrane mimetic solvent. Antimicrob Agents Chemother 49:3387-95.
156. Hunter, H. N., W. Jing, D. J. Schibli, T. Trinh, I. Y. Park, S. C. Kim, and H. J. Vogel. 2005. The interactions of antimicrobial peptides derived from lysozyme with model membrane systems. Biochim Biophys Acta 1668:175-89.
157. Huth, P. J., D. B. DiRienzo, and G. D. Miller. 2006. Major scientific advances with dairy foods in nutrition and health. J Dairy Sci 89:1207-21.
158. Hwang, P. M., N. Zhou, X. Shan, C. H. Arrowsmith, and H. J. Vogel. 1998. Three-dimensional solution structure of lactoferricin B, an antimicrobial peptide derived from bovine lactoferrin. Biochemistry 37:4288-98.
159. Iida, J., A. M. Meijne, T. R. Oegema, Jr., T. A. Yednock, N. L. Kovach, L. T. Furcht, and J. B. McCarthy. 1998. A role of chondroitin sulfate glycosaminoglycan binding site in alpha4beta1 integrin-mediated melanoma cell adhesion. J Biol Chem 273:5955-62.
160. Ikeda, M., A. Nozaki, K. Sugiyama, T. Tanaka, A. Naganuma, K. Tanaka, H. Sekihara, K. Shimotohno, M. Saito, and N. Kato. 2000. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res 66:51-63.
161. Ikeda, M., K. Sugiyama, T. Tanaka, K. Tanaka, H. Sekihara, K. Shimotohno, and N. Kato. 1998. Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem Biophys Res Commun 245:549-53.
162. Iozzo, R. V., and A. D. Murdoch. 1996. Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. Faseb J 10:598-614.
163. Ishikado, A., H. Imanaka, M. Kotani, A. Fujita, Y. Mitsuishi, T. Kanemitsu, Y. Tamura, and T. Makino. 2004. Liposomal lactoferrin induced significant increase of the interferon-alpha (IFN-alpha) producibility in healthy volunteers. Biofactors 21:69-72.
164. James, S., B. F. Gibbs, K. Toney, and H. P. Bennett. 1994. Purification of antimicrobial peptides from an extract of the skin of Xenopus laevis using heparin-affinity HPLC: characterization by ion-spray mass spectrometry. Anal Biochem 217:84-90.
165. Jarvis, K. G., J. A. Giron, A. E. Jerse, T. K. McDaniel, M. S. Donnenberg, and J. B. Kaper. 1995. Enteropathogenic Escherichia coli contains a putative type III secretion system necessary for the export of proteins involved in attaching and effacing lesion formation. Proc Natl Acad Sci U S A 92:7996-8000.
166. Javadpour, M. M., M. M. Juban, W. C. Lo, S. M. Bishop, J. B. Alberty, S. M. Cowell, C. L. Becker, and M. L. McLaughlin. 1996. De novo antimicrobial peptides with low mammalian cell toxicity. J Med Chem 39:3107-13.
167. Jenssen, H. 2005. Anti herpes simplex virus activity of lactoferrin/lactoferricin -- an example of antiviral activity of antimicrobial protein/peptide. Cell Mol Life Sci 62:3002-13.
168. Jenssen, H., J. H. Andersen, D. Mantzilas, and T. J. Gutteberg. 2004. A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus. Antiviral Res 64:119-26.
169. Jenssen, H., J. H. Andersen, L. Uhlin-Hansen, T. J. Gutteberg, and O. Rekdal. 2004. Anti-HSV activity of lactoferricin analogues is only partly related to their affinity for heparan sulfate. Antiviral Res 61:101-9.
170. Jenssen, H., T. J. Gutteberg, and T. Lejon. 2005. Modelling of anti-HSV activity of lactoferricin analogues using amino acid descriptors. J Pept Sci 11:97-103.
171. Jenssen, H., T. J. Gutteberg, and T. Lejon. 2006. Modelling the anti-herpes simplex virus activity of small cationic peptides using amino acid descriptors. J Pept Res 66 (suppl. 1):48-56.
172. Jenssen, H., P. Hamill, and R. E. W. Hancock. 2006. Peptide antimicrobial agents. Clin Microbiol Rev 19:491-511.
173. Ji, Z. S., and R. W. Mahley. 1994. Lactoferrin binding to heparan sulfate proteoglycans and the LDL receptor-related protein. Further evidence supporting the importance of direct binding of remnant lipoproteins to HSPG. Arterioscler Thromb 14:2025-31.
174. Johnstone, S. A., K. Gelmon, L. D. Mayer, R. E. W. Hancock, and M. B. Bally. 2000. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and pglycoprotein over-expressing tumor cell lines. Anticancer Drug Des 15:151-60.
175. Joyce, J. G., J. S. Tung, C. T. Przysiecki, J. C. Cook, E. D. Lehman, J. A. Sands, K. U. Jansen, and P. M. Keller. 1999. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 274:5810-22.
176. Kai, K., K. Komine, Y. Komine, T. Kuroishi, T. Kozutsumi, J. Kobayashi, M. Ohta, H. Kitamura, and K. Kumagai. 2002. Lactoferrin stimulates A Staphylococcus aureus killing activity of bovine phagocytes in the mammary gland. Microbiol Immunol 46:187-94.
177. Kalmar, J. R., and R. R. Arnold. 1988. Killing of Actinobacillus actinomycetemcomitans by human lactoferrin. Infect Immun 56:2552-7.
178. Kang, J. H., M. K. Lee, K. L. Kim, and K. S. Hahm. 1996. Structurebiological activity relationships of 11-residue highly basic peptide segment of bovine lactoferrin. Int J Pept Protein Res 48:357-63.
179. Kaniga, K., D. Trollinger, and J. E. Galan. 1995. Identification of two targets of the type III protein secretion system encoded by the inv and spa loci of Salmonella typhimurium that have homology to the Shigella IpaD and IpaA proteins. J Bacteriol 177:7078-85.
180. Kanyshkova, T. G., D. V. Semenov, V. N. Buneva, and G. A. Nevinsky. 1999. Human milk lactoferrin binds two DNA molecules with different affinities. FEBS Lett 451:235-7.
181. Kawakami, H., and B. Lonnerdal. 1991. Isolation and function of a receptor for human lactoferrin in human fetal intestinal brush-border membranes. Am J Physiol 261:G841-6.
182. Khan, J. A., P. Kumar, M. Paramasivam, R. S. Yadav, M. S. Sahani, S. Sharma, A. Srinivasan, and T. P. Singh. 2001. Camel lactoferrin, a transferrin-cum-lactoferrin: crystal structure of camel apolactoferrin at 2.6 A resolution and structural basis of its dual role. J Mol Biol 309:751-61.
183. Kim, H. H., W. S. Lee, J. M. Yang, and S. Shin. 2003. Basic peptide system for efficient delivery of foreign genes. Biochim Biophys Acta 1640:129-36.
184. Kirkpatrick, C. H., I. Green, R. R. Rich, and A. L. Schade. 1971. Inhibition of growth of Candida albicans by iron-unsaturated lactoferrin: relation to host-defense mechanisms in chronic mucocutaneous candidiasis. J Infect Dis 124:539-44.
185. Kjellen, L., and U. Lindahl. 1991. Proteoglycans: structures and interactions. Annu Rev Biochem 60:443-75.
186. Koczulla, R., G. von Degenfeld, C. Kupatt, F. Krotz, S. Zahler, T. Gloe, K. Issbrucker, P. Unterberger, M. Zaiou, C. Lebherz, A. Karl, P. Raake, A. Pfosser, P. Boekstegers, U. Welsch, P. S. Hiemstra, C. Vogelmeier, R. L. Gallo, M. Clauss, and R. Bals. 2003. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 111:1665-72.
187. Kolset, S. O., and J. T. Gallagher. 1990. Proteoglycans in haemopoietic cells. Biochim Biophys Acta 1032:191-211.
188. Konishi, M., M. Iwasa, K. Yamauchi, R. Sugimoto, N. Fujita, Y. Kobayashi, S. Watanabe, S. Teraguchi, Y. Adachi, and M. Kaito. 2006. Lactoferrin inhibits lipid peroxidation in patients with chronic hepatitis C. Hepatol Res. 36:27-32.
189. Koradi, R., M. Billeter, and K. Wuthrich. 1996. MOLMOL: a program for display and analysis of macromolecular structures. J Mol Graph 14:51-5, 29-32.
190. Koshlukova, S. E., M. W. Araujo, D. Baev, and M. Edgerton. 2000. Released ATP is an extracellular cytotoxic mediator in salivary histatin 5- induced killing of Candida albicans. Infect Immun 68:6848-56.
191. Koshlukova, S. E., T. L. Lloyd, M. W. Araujo, and M. Edgerton. 1999. Salivary histatin 5 induces non-lytic release of ATP from Candida albicans leading to cell death. J Biol Chem 274:18872-9.
192. Kroemer, G., B. Dallaporta, and M. Resche-Rigon. 1998. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 60:619-42.
193. Kuhara, T., K. Yamauchi, Y. Tamura, and H. Okamura. 2006. Oral Administration of Lactoferrin Increases NK Cell Activity in Mice via Increased Production of IL-18 and Type I IFN in the Small Intestine. J Interferon Cytokine Res 26:489-99.
194. Kuipers, M. E., H. G. de Vries, M. C. Eikelboom, D. K. Meijer, and P. J. Swart. 1999. Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicrob Agents Chemother 43:2635-41.
195. Kullberg, B. J., M. G. Netea, A. G. Vonk, and J. W. van der Meer. 1999. Modulation of neutrophil function in host defense against disseminated Candida albicans infection in mice. FEMS Immunol Med Microbiol 26:299-307.
196. Kumar, S., and K. L. Bhatia. 1988. Characterization of buffalo lactotransferrin by polyacrylamide gel electrophoresis in 6 M urea. J Chromatogr 434:228-31.
197. Kustanovich, I., D. E. Shalev, M. Mikhlin, L. Gaidukov, and A. Mor. 2002. Structural requirements for potent versus selective cytotoxicity for antimicrobial dermaseptin S4 derivatives. J Biol Chem 277:16941-51.
198. Kuwata, H., T. T. Yip, K. Yamauchi, S. Teraguchi, H. Hayasawa, M. Tomita, and T. W. Hutchens. 1998. The survival of ingested lactoferrin in the gastrointestinal tract of adult mice. Biochem J 334 (Pt 2):321-3.
199. Kyte, J., and R. F. Doolittle. 1982. A simple method for displaying the hydropathic character of a protein. J Mol Biol 157:105-32.
200. Lau, Y. E., A. Rozek, M. G. Scott, D. L. Goosney, D. J. Davidson, and R. E. W. Hancock. 2005. Interaction and cellular localization of the human host defense peptide LL-37 with lung epithelial cells. Infect Immun 73:583-91.
201. Lee, D. G., Y. Park, I. Jin, K. S. Hahm, H. H. Lee, Y. H. Moon, and E. R. Woo. 2004. Structure-antiviral activity relationships of cecropin Amagainin 2 hybrid peptide and its analogues. J Pept Sci 10:298-303.
202. Legrand, D., K. Vigie, E. A. Said, E. Elass, M. Masson, M. C. Slomianny, M. Carpentier, J. P. Briand, J. Mazurier, and A. G. Hovanessian. 2004. Surface nucleolin participates in both the binding and endocytosis of lactoferrin in target cells. Eur J Biochem 271:303-17.
203. Lehrer, R. I., A. Barton, K. A. Daher, S. S. Harwig, T. Ganz, and M. E. Selsted. 1989. Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity. J Clin Invest 84:553-61.
204. Leitch, E. C., and M. D. Willcox. 1999. Elucidation of the antistaphylococcal action of lactoferrin and lysozyme. J Med Microbiol 48:867-71.
205. Leitch, E. C., and M. D. Willcox. 1999. Lactoferrin increases the susceptibility of S. epidermidis biofilms to lysozyme and vancomycin. Curr Eye Res 19:12-9.
206. Levay, P. F., and M. Viljoen. 1995. Lactoferrin: a general review. Haematologica 80:252-67.
207. Lewis, L. A., K. Rohde, M. Gipson, B. Behrens, E. Gray, S. I. Toth, B. A. Roe, and D. W. Dyer. 1998. Identification and molecular analysis of lbpBA, which encodes the two-component meningococcal lactoferrin receptor. Infect Immun 66:3017-23.
208. Li, J., J. F. Revol, E. Naranjo, and R. H. Marchessault. 1996. Effect of electrostatic interaction on phase separation behaviour of chitin crystallite suspensions. Int J Biol Macromol 18:177-87.
209. Lim, D. J., Y. M. Chun, H. Y. Lee, S. K. Moon, K. H. Chang, J. D. Li, and A. Andalibi. 2000. Cell biology of tubotympanum in relation to pathogenesis of otitis media - a review. Vaccine 19 Suppl 1:S17-25.
210. Lin, T. Y., C. Chu, and C. H. Chiu. 2002. Lactoferrin inhibits enterovirus 71 infection of human embryonal rhabdomyosarcoma cells in vitro. J Infect Dis 186:1161-4.
211. Lookene, A., R. Savonen, and G. Olivecrona. 1997. Interaction of lipoproteins with heparan sulfate proteoglycans and with lipoprotein lipase. Studies by surface plasmon resonance technique. Biochemistry 36:5267-75.
212. Lopez-Garcia, B., J. F. Marcos, C. Abad, and E. Perez-Paya. 2004. Stabilisation of mixed peptide/lipid complexes in selective antifungal hexapeptides. Biochim Biophys Acta 1660:131-7.
213. Loukas, S., D. Varoucha, C. Zioudrou, R. A. Streaty, and W. A. Klee. 1983. Opioid activities and structures of alpha-casein-derived exorphins. Biochemistry 22:4567-73.
214. Lupetti, A., A. Paulusma-Annema, S. Senesi, M. Campa, J. T. Van Dissel, and P. H. Nibbering. 2002. Internal thiols and reactive oxygen species in candidacidal activity exerted by an N-terminal peptide of human lactoferrin. Antimicrob Agents Chemother 46:1634-9.
215. Lupetti, A., A. Paulusma-Annema, M. M. Welling, S. Senesi, J. T. van Dissel, and P. H. Nibbering. 2000. Candidacidal activities of human lactoferrin peptides derived from the N terminus. Antimicrob Agents Chemother 44:3257-63.
216. Lustig, F., J. Hoebeke, G. Ostergren-Lunden, F. Velge-Roussel, G. Bondjers, U. Olsson, U. Ruetschi, and G. Fager. 1996. Alternative splicing determines the binding of platelet-derived growth factor (PDGF-AA) to glycosaminoglycans. Biochemistry 35:12077-85.
217. Mader, J. S., J. Salsman, D. M. Conrad, and D. W. Hoskin. 2005. Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol Cancer Ther 4:612-24.
218. Mai, J. C., Z. Mi, S. H. Kim, B. Ng, and P. D. Robbins. 2001. A proapoptotic peptide for the treatment of solid tumors. Cancer Res 61:7709-12.
219. Mandard, N., P. Sodano, H. Labbe, J. M. Bonmatin, P. Bulet, C. Hetru, M. Ptak, and F. Vovelle. 1998. Solution structure of thanatin, a potent bactericidal and fungicidal insect peptide, determined from proton twodimensional nuclear magnetic resonance data. Eur J Biochem 256:404-10.
220. Mann, D. M., E. Romm, and M. Migliorini. 1994. Delineation of the glycosaminoglycan-binding site in the human inflammatory response protein lactoferrin. J Biol Chem 269:23661-7.
221. Marchetti, M., C. Longhi, M. P. Conte, S. Pisani, P. Valenti, and L. Seganti. 1996. Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cells. Antiviral Res 29:221-31.
222. Marchetti, M., S. Pisani, G. Antonini, P. Valenti, L. Seganti, and N. Orsi. 1998. Metal complexes of bovine lactoferrin inhibit in vitro replication of herpes simplex virus type 1 and 2. Biometals 11:89-94.
223. Marchetti, M., F. Superti, M. G. Ammendolia, P. Rossi, P. Valenti, and L. Seganti. 1999. Inhibition of poliovirus type 1 infection by iron-, manganeseand zinc-saturated lactoferrin. Med Microbiol Immunol (Berl) 187:199-204.
224. Marchetti, M., E. Trybala, F. Superti, M. Johansson, and T. Bergstrom. 2004. Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans. Virology 318:405-13.
225. Mardberg, K., E. Trybala, F. Tufaro, and T. Bergstrom. 2002. Herpes simplex virus type 1 glycoprotein C is necessary for efficient infection of chondroitin sulfate-expressing gro2C cells. J Gen Virol 83:291-300.
226. Marr, A. K., W. J. Gooderham, and R. E. W. Hancock. 2006. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol.
227. Marshall, K. 2004. Therapeutic applications of whey protein. Altern Med Rev 9:136-56.
228. Masson, P., J. F. Heremans, and J. Prignot. 1965. Immunohistochemical localization of the iron-binding protein lactoferrin in human bronchial glands. Experientia 21:604-5.
229. Masson, P. L., and J. F. Heremans. 1971. Lactoferrin in milk from different species. Comp Biochem Physiol B 39:119-29.
230. Masson, P. L., J. F. Heremans, and C. Dive. 1966. Studies of the proteins of secretions from two villous tumours of the rectum. Gastroenterologia 105:270-82.
231. Matsuzaki, K., O. Murase, N. Fujii, and K. Miyajima. 1996. An antimicrobial peptide, magainin 2, induced rapid flip-flop of phospholipids coupled with pore formation and peptide translocation. Biochemistry 35:11361-8.
232. Matsuzaki, K., K. Sugishita, N. Ishibe, M. Ueha, S. Nakata, K. Miyajima, and R. M. Epand. 1998. Relationship of membrane curvature to the formation of pores by magainin 2. Biochemistry 37:11856-63.
233. Mazoyer, E., S. Levy-Toledano, F. Rendu, L. Hermant, H. Lu, A. M. Fiat, P. Jolles, and J. Caen. 1990. KRDS, a new peptide derived from human lactotransferrin, inhibits platelet aggregation and release reaction. Eur J Biochem 194:43-9.
234. Mazurier, J., D. Legrand, W. L. Hu, J. Montreuil, and G. Spik. 1989. Expression of human lactotransferrin receptors in phytohemagglutininstimulated human peripheral blood lymphocytes. Isolation of the receptors by antiligand-affinity chromatography. Eur J Biochem 179:481-7.
235. McAbee, D. D., and K. Esbensen. 1991. Binding and endocytosis of apoand holo-lactoferrin by isolated rat hepatocytes. J Biol Chem 266:23624-31.
236. McCann, K. B., A. Lee, J. Wan, H. Roginski, and M. J. Coventry. 2003. The effect of bovine lactoferrin and lactoferricin B on the ability of feline calicivirus (a norovirus surrogate) and poliovirus to infect cell cultures. J Appl Microbiol 95:1026-33.
237. McKeown, S. T., F. T. Lundy, J. Nelson, D. Lockhart, C. R. Irwin, C. G. Cowan, and J. J. Marley. 2006. The cytotoxic effects of human neutrophil peptide-1 (HNP1) and lactoferrin on oral squamous cell carcinoma (OSCC) in vitro. Oral Oncol. 42:685-90
238. McManus, A. M., N. F. Dawson, J. D. Wade, L. E. Carrington, D. J. Winzor, and D. J. Craik. 2000. Three-dimensional structure of RK-1: a novel alpha-defensin peptide. Biochemistry 39:15757-64.
239. McMillan, N. A., E. Payne, I. H. Frazer, and M. Evander. 1999. Expression of the alpha6 integrin confers papillomavirus binding upon receptornegative B-cells. Virology 261:271-9.
240. Mettenleiter, T. C. 2002. Brief overview on cellular virus receptors. Virus Res 82:3-8.
241. Mikloska, Z., and A. L. Cunningham. 2001. Alpha and gamma interferons inhibit herpes simplex virus type 1 infection and spread in epidermal cells after axonal transmission. J Virol 75:11821-6.
242. Mistry, N., P. Drobni, J. Naslund, V. G. Sunkari, H. Jenssen, and E. M. 2007. The anti-papillomavirus activity of human and bovine lactoferricin. Antiviral Res (In press).
243. Miyagi, T., T. Wada, K. Yamaguchi, and K. Hata. 2004. Sialidase and malignancy: a minireview. Glycoconj J 20:189-98.
244. Moore, S. A., B. F. Anderson, C. R. Groom, M. Haridas, and E. N. Baker. 1997. Three-dimensional structure of diferric bovine lactoferrin at 2.8 A resolution. J Mol Biol 274:222-36.
245. Murphy, M. E., H. Kariwa, T. Mizutani, H. Tanabe, K. Yoshimatsu, J. Arikawa, and I. Takashima. 2001. Characterization of in vitro and in vivo antiviral activity of lactoferrin and ribavirin upon hantavirus. J Vet Med Sci 63:637-45.
246. Murphy, M. E., H. Kariwa, T. Mizutani, K. Yoshimatsu, J. Arikawa, and I. Takashima. 2000. In vitro antiviral activity of lactoferrin and ribavirin upon hantavirus. Arch Virol 145:1571-82.
247. Nakashima, H., M. Masuda, T. Murakami, Y. Koyanagi, A. Matsumoto, N. Fujii, and N. Yamamoto. 1992. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion. Antimicrob Agents Chemother 36:1249-55.
248. Nguyen, L. T., D. J. Schibli, and H. J. Vogel. 2005. Structural studies and model membrane interactions of two peptides derived from bovine lactoferricin. J Pept Sci 11:379-89.
249. Nibbering, P. H., E. Ravensbergen, M. M. Welling, L. A. van Berkel, P. H. van Berkel, E. K. Pauwels, and J. H. Nuijens. 2001. Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infect Immun 69:1469-76.
250. Nikaido, H., and M. Vaara. 1985. Molecular basis of bacterial outer membrane permeability. Microbiol Rev 49:1-32.
251. Nikawa, H., H. Fukushima, S. Makihira, T. Hamada, and L. P. Samaranayake. 2004. Fungicidal effect of three new synthetic cationic peptides against Candida albicans. Oral Dis 10:221-8.
252. Nikawa, H., L. P. Samaranayake, and T. Hamada. 1995. Modulation of the anti-Candida activity of apo-lactoferrin by dietary sucrose and tunicamycin in vitro. Arch Oral Biol 40:581-4.
253. Nikawa, H., L. P. Samaranayake, J. Tenovuo, K. M. Pang, and T. Hamada. 1993. The fungicidal effect of human lactoferrin on Candida albicans and Candida krusei. Arch Oral Biol 38:1057-63.
254. Norris, G. E., B. F. Anderson, and E. N. Baker. 1991. Molecular replacement solution of the structure of apolactoferrin, a protein displaying large-scale conformational change. Acta Crystallogr B 47 (Pt 6):998-1004.
255. Ochoa, T. J., and T. G. Clearly. 2004. Lactoferrin disruption of bacterial type III secretion systems. Biometals 17:257-60.
256. Ochoa, T. J., M. Noguera-Obenza, and T. G. Cleary. 2004. Lactoferrin blocks the initial host cell attachment mechanism of Enteropathogenic E. coli (EPEC). Adv Exp Med Biol 554:463-6.
257. Ochoa, T. J., M. Noguera-Obenza, F. Ebel, C. A. Guzman, H. F. Gomez, and T. G. Cleary. 2003. Lactoferrin impairs type III secretory system function in enteropathogenic Escherichia coli. Infect Immun 71:5149-55.
258. Odeh, R., and J. P. Quinn. 2000. Problem pulmonary pathogens:Pseudomonas aeruinosa. Semin Respir Crit Care Med 21:331-9.
259. Odell, E. W., R. Sarra, M. Foxworthy, D. S. Chapple, and R. W. Evans. 1996. Antibacterial activity of peptides homologous to a loop region in human lactoferrin. FEBS Lett 382:175-8.
260. Ohsaki, Y., A. F. Gazdar, H. C. Chen, and B. E. Johnson. 1992. Antitumor activity of magainin analogues against human lung cancer cell lines. Cancer Res 52:3534-8.
261. Okada, S., K. Tanaka, T. Sato, H. Ueno, S. Saito, T. Okusaka, K. Sato, S. Yamamoto, and T. Kakizoe. 2002. Dose-response trial of lactoferrin in patients with chronic hepatitis C. Jpn J Cancer Res 93:1063-9.
262. Olsson, U., G. Camejo, E. Hurt-Camejo, K. Elfsber, O. Wiklund, and G. Bondjers. 1997. Possible functional interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the ApoB/E receptor. Arterioscler Thromb Vasc Biol 17:149-55.
263. Omata, Y., M. Satake, R. Maeda, A. Saito, K. Shimazaki, K. Yamauchi, Y. Uzuka, S. Tanabe, T. Sarashina, and T. Mikami. 2001. Reduction of the infectivity of Toxoplasma gondii and Eimeria stiedai sporozoites by treatment with bovine lactoferricin. J Vet Med Sci 63:187-90.
264. Oppenheim, F. G., T. Xu, F. M. McMillian, S. M. Levitz, R. D. Diamond, G. D. Offner, and R. F. Troxler. 1988. Histatins, a novel family of histidinerich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J Biol Chem 263:7472-7.
265. Oyane, A., Y. Yokoyama, M. Uchida, and A. Ito. 2006. The formation of an antibacterial agent-apatite composite coating on a polymer surface using a metastable calcium phosphate solution. Biomaterials 27:3295-303.
266. Park, C. B., H. S. Kim, and S. C. Kim. 1998. Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun 244:253-7.
267. Park, Y., S. H. Jang, D. G. Lee, and K. S. Hahm. 2004. Antinematodal effect of antimicrobial peptide, PMAP-23, isolated from porcine myeloid against Caenorhabditis elegans. J Pept Sci 10:304-11.
268. Parker, K. H., C. P. Winlove, and A. Maroudas. 1988. The theoretical distributions and diffusivities of small ions in chondroitin sulphate and hyaluronate. Biophys Chem 32:271-82.
269. Patrzykat, A., C. L. Friedrich, L. Zhang, V. Mendoza, and R. E. W. Hancock. 2002. Sublethal Concentrations of Pleurocidin-Derived Antimicrobial Peptides Inhibit Macromolecular Synthesis in Escherichia coli. Antimicrob. Agents Chemother. 46:605-614.
270. Patterson, N. A., J. L. Smith, and M. A. Ozbun. 2005. Human papillomavirus type 31b infection of human keratinocytes does not require heparan sulfate. J Virol 79:6838-47.
271. Penco, S., S. Scarfi, M. Giovine, G. Damonte, E. Millo, B. Villaggio, M. Passalacqua, M. Pozzolini, C. Garre, and U. Benatti. 2001. Identification of an import signal for, and the nuclear localization of, human lactoferrin. Biotechnol Appl Biochem 34:151-9.
272. Pettersson, A., T. Prinz, A. Umar, J. van der Biezen, and J. Tommassen. 1998. Molecular characterization of LbpB, the second lactoferrin-binding protein of Neisseria meningitidis. Mol Microbiol 27:599-610.
273. Pettersson, I., M. Kusche, E. Unger, H. Wlad, L. Nylund, U. Lindahl, and L. Kjellen. 1991. Biosynthesis of heparin. Purification of a 110-kDa mouse mastocytoma protein required for both glucosaminyl N-deacetylation and N-sulfation. J Biol Chem 266:8044-9.
274. Pierce, A., D. Colavizza, M. Benaissa, P. Maes, A. Tartar, J. Montreuil, and G. Spik. 1991. Molecular cloning and sequence analysis of bovine lactotransferrin. Eur J Biochem 196:177-84.
275. Pietrantoni, A., M. G. Ammendolia, A. Tinari, R. Siciliano, P. Valenti, and F. Superti. 2006. Bovine lactoferrin peptidic fragments involved in inhibition of Echovirus 6 in vitro infection. Antiviral Res 69:98-106.
276. Pietrantoni, A., A. M. Di Biase, A. Tinari, M. Marchetti, P. Valenti, L. Seganti, and F. Superti. 2003. Bovine lactoferrin inhibits adenovirus infection by interacting with viral structural polypeptides. Antimicrob Agents Chemother 47:2688-91.
277. Platenburg, G. J., E. P. Kootwijk, P. M. Kooiman, S. L. Woloshuk, J. H. Nuijens, P. J. Krimpenfort, F. R. Pieper, H. A. de Boer, and R. Strijker. 1994. Expression of human lactoferrin in milk of transgenic mice. Transgenic Res 3:99-108.
278. Pollock, J. J., L. Denepitiya, B. J. MacKay, and V. J. Iacono. 1984. Fungistatic and fungicidal activity of human parotid salivary histidine-rich polypeptides on Candida albicans. Infect Immun 44:702-7.
279. Portelli, J., A. Gordon, and J. T. May. 1998. Effect of compounds with antibacterial activities in human milk on respiratory syncytial virus and cytomegalovirus in vitro. J Med Microbiol 47:1015-8.
280. Pouny, Y., D. Rapaport, A. Mor, P. Nicolas, and Y. Shai. 1992. Interaction of antimicrobial dermaseptin and its fluorescently labeled analogues with phospholipid membranes. Biochemistry 31:12416-23.
281. Powers, J. P., A. Rozek, and R. E. W. Hancock. 2004. Structure-activity relationships for the beta-hairpin cationic antimicrobial peptide polyphemusin I. Biochim Biophys Acta 1698:239-50.
282. Powers, J. P., A. Tan, A. Ramamoorthy, and R. E. W. Hancock. 2005. Solution structure and interaction of the antimicrobial polyphemusins with lipid membranes. Biochemistry 44:15504-13.
283. Prinz, T., and J. Tommassen. 2000. Association of iron-regulated outer membrane proteins of Neisseria meningitidis with the RmpM (class 4) protein. FEMS Microbiol Lett 183:49-53.
284. Puddu, P., P. Borghi, S. Gessani, P. Valenti, F. Belardelli, and L. Seganti. 1998. Antiviral effect of bovine lactoferrin saturated with metal ions on early steps of human immunodeficiency virus type 1 infection. Int J Biochem Cell Biol 30:1055-62.
285. Qiu, J., D. R. Hendrixson, E. N. Baker, T. F. Murphy, J. W. St Geme, 3rd, and A. G. Plaut. 1998. Human milk lactoferrin inactivates two putative colonization factors expressed by Haemophilus influenzae. Proc Natl Acad Sci U S A 95:12641-6.
286. Raval, G. N., D. D. Patel, L. J. Parekh, J. B. Patel, M. H. Shah, and P. S. Patel. 2003. Evaluation of serum sialic acid, sialyltransferase and sialoproteins in oral cavity cancer. Oral Dis 9:119-28.
287. Recio, I., C. J. Slangen, and S. Visser. 2000. Method for the production of antibacterial peptides from biological fluids at an ionic membrane. Application to the isolation of nisin and caprine lactoferricin. Le Lait 80:187-195.
288. Retegui, L. A., N. Moguilevsky, C. F. Castracane, and P. L. Masson. 1984. Uptake of lactoferrin by the liver. I. Role of the reticuloendothelial system as indicated by blockade experiments. Lab Invest 50:323-8.
289. Rey, M. W., S. L. Woloshuk, H. A. deBoer, and F. R. Pieper. 1990. Complete nucleotide sequence of human mammary gland lactoferrin. Nucleic Acids Res 18:5288.
290. Rice, P. J., J. L. Kelley, G. Kogan, H. E. Ensley, J. H. Kalbfleisch, I. W. Browder, and D. L. Williams. 2002. Human monocyte scavenger receptors are pattern recognition receptors for (1-->3)-beta-D-glucans. J Leukoc Biol 72:140-6.
291. Risso, A., E. Braidot, M. C. Sordano, A. Vianello, F. Macri, B. Skerlavaj, M. Zanetti, R. Gennaro, and P. Bernardi. 2002. BMAP-28, an antibiotic peptide of innate immunity, induces cell death through opening of the mitochondrial permeability transition pore. Mol Cell Biol 22:1926-35.
292. Robinson, W. E., Jr., B. McDougall, D. Tran, and M. E. Selsted. 1998. Anti-HIV-1 activity of indolicidin, an antimicrobial peptide from neutrophils. J Leukoc Biol 63:94-100.
293. Rochard, E., D. Legrand, M. Lecocq, R. Hamelin, M. Crepin, J. Montreuil, and G. Spik. 1992. Characterization of lactotransferrin receptor in epithelial cell lines from non-malignant human breast, benign mastopathies and breast carcinomas. Anticancer Res 12:2047-51.
294. Rossi, P., F. Giansanti, A. Boffi, M. Ajello, P. Valenti, E. Chiancone, and G. Antonini. 2002. Ca2+ binding to bovine lactoferrin enhances protein stability and influences the release of bacterial lipopolysaccharide. Biochem Cell Biol 80:41-8.
295. Sakamoto, K., Y. Ito, T. Mori, and K. Sugimura. 2006. Interaction of human lactoferrin with cell adhesion molecules through RGD motif elucidated by lactoferrin-binding epitopes. J Biol Chem 281:24472-8.
296. Salmon, V., D. Legrand, M. C. Slomianny, I. el Yazidi, G. Spik, V. Gruber, P. Bournat, B. Olagnier, D. Mison, M. Theisen, and B. Merot. 1998. Production of human lactoferrin in transgenic tobacco plants. Protein Expr Purif 13:127-35.
297. Samuelsen, O., H. H. Haukland, H. Jenssen, M. Kramer, K. Sandvik, H. Ulvatne, and L. H. Vorland. 2005. Induced resistance to the antimicrobial peptide lactoferricin B in Staphylococcus aureus. FEBS Lett 579:3421-6.
298. Samuelsen, O., H. H. Haukland, B. C. Kahl, C. von Eiff, R. A. Proctor, H. Ulvatne, K. Sandvik, and L. H. Vorland. 2005. Staphylococcus aureus small colony variants are resistant to the antimicrobial peptide lactoferricin B. J Antimicrob Chemother 56:1126-9.
299. Schmidtke, M., A. Karger, A. Meerbach, R. Egerer, A. Stelzner, and V. Makarov. 2003. Binding of a N, N’-bisheteryl derivative of dispirotripiperazine to heparan sulfate residues on the cell surface specifically prevents infection of viruses from different families. Virology 311:134-43.
300. Seganti, L., A. M. Di Biase, M. Marchetti, A. Pietrantoni, A. Tinari, and F. Superti. 2004. Antiviral activity of lactoferrin towards naked viruses. Biometals 17:295-9.
301. Selinka, H. C., T. Giroglou, T. Nowak, N. D. Christensen, and M. Sapp. 2003. Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol 77:12961-7.
302. Selinka, H. C., T. Giroglou, and M. Sapp. 2002. Analysis of the infectious entry pathway of human papillomavirus type 33 pseudovirions. Virology 299:279-287.
303. Selsted, M. E. 2004. Theta-defensins: cyclic antimicrobial peptides produced by binary ligation of truncated alpha-defensins. Curr Protein Pept Sci 5:365-71.
304. Sfeir, R. M., M. Dubarry, P. N. Boyaka, M. Rautureau, and D. Tome. 2004. The mode of oral bovine lactoferrin administration influences mucosal and systemic immune responses in mice. J Nutr 134:403-9.
305. Shafti-Keramat, S., A. Handisurya, E. Kriehuber, G. Meneguzzi, K. Slupetzky, and R. Kirnbauer. 2003. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol 77:13125-35.
306. Shakibaei, M., and U. Frevert. 1996. Dual interaction of the malaria circumsporozoite protein with the low density lipoprotein receptor-related protein (LRP) and heparan sulfate proteoglycans. J Exp Med 184:1699-711.
307. Shau, H., A. Kim, and S. H. Golub. 1992. Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin. J Leukoc Biol 51:343-9.
308. Shieh, M. T., D. WuDunn, R. I. Montgomery, J. D. Esko, and P. G. Spear. 1992. Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. J Cell Biol 116:1273-81.
309. Shimazaki, K., K. Oota, K. Nitta, and Y. Ke. 1994. Comparative study of the iron-binding strengths of equine, bovine and human lactoferrins. J Dairy Res 61:563-6.
310. Shimazaki, K., T. Tazume, K. Uji, M. Tanaka, H. Kumura, K. Mikawa, and T. Shimo-Oka. 1998. Properties of a heparin-binding peptide derived from bovine lactoferrin. J Dairy Sci 81:2841-9.
311. Shin, K., H. Wakabayashi, K. Yamauchi, S. Teraguchi, Y. Tamura, M. Kurokawa, and K. Shiraki. 2005. Effects of orally administered bovine lactoferrin and lactoperoxidase on influenza virus infection in mice. J Med Microbiol 54:717-23.
312. Shin, K., K. Yamauchi, S. Teraguchi, H. Hayasawa, M. Tomita, Y. Otsuka, and S. Yamazaki. 1998. Antibacterial activity of bovine lactoferrin and its peptides against enterohaemorrhagic Escherichia coli O157:H7. Lett Appl Microbiol 26:407-11.
313. Shukla, D., J. Liu, P. Blaiklock, N. W. Shworak, X. Bai, J. D. Esko, G. H. Cohen, R. J. Eisenberg, R. D. Rosenberg, and P. G. Spear. 1999. A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 99:13-22.
314. Siciliano, R., B. Rega, M. Marchetti, L. Seganti, G. Antonini, and P. Valenti. 1999. Bovine lactoferrin peptidic fragments involved in inhibition of herpes simplex virus type 1 infection. Biochem Biophys Res Commun 264:19-23.
315. Singh, P. K., M. R. Parsek, E. P. Greenberg, and M. J. Welsh. 2002. A component of innate immunity prevents bacterial biofilm development. Nature 417:552-5.
316. Singh, P. K., B. F. Tack, P. B. McCray, Jr., and M. J. Welsh. 2000. Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am J Physiol Lung Cell Mol Physiol 279:L799-805.
317. Sinha, S., N. Cheshenko, R. I. Lehrer, and B. C. Herold. 2003. NP-1, a rabbit alpha-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2. Antimicrob Agents Chemother 47:494-500.
318. Sinnis, P., T. E. Willnow, M. R. Briones, J. Herz, and V. Nussenzweig. 1996. Remnant lipoproteins inhibit malaria sporozoite invasion of hepatocytes. J Exp Med 184:945-54.
319. Sitaram, N., and R. Nagaraj. 1999. Interaction of antimicrobial peptides with biological and model membranes: structural and charge requirements for activity. Biochim Biophys Acta 1462:29-54.
320. Son, K. N., J. Park, C. K. Chung, D. K. Chung, D. Y. Yu, K. K. Lee, and J. Kim. 2002. Human lactoferrin activates transcription of IL-1beta gene in mammalian cells. Biochem Biophys Res Commun 290:236-41.
321. Song, B. H., G. C. Lee, M. S. Moon, Y. H. Cho, and C. H. Lee. 2001. Human cytomegalovirus binding to heparan sulfate proteoglycans on the cell surface and/or entry stimulates the expression of human leukocyte antigen class I. J Gen Virol 82:2405-13.
322. Song, Y. M., Y. Park, S. S. Lim, S. T. Yang, E. R. Woo, I. S. Park, J. S. Lee, J. I. Kim, K. S. Hahm, Y. Kim, and S. Y. Shin. 2005. Cell selectivity and mechanism of action of antimicrobial model peptides containing peptoid residues. Biochemistry 44:12094-106.
323. Soukka, T., J. Tenovuo, and M. Lenander-Lumikari. 1992. Fungicidal effect of human lactoferrin against Candida albicans. FEMS Microbiol Lett 69:223-8.
324. Spaar, A., C. Munster, and T. Salditt. 2004. Conformation of peptides in lipid membranes studied by x-ray grazing incidence scattering. Biophys J 87:396-407.
325. Spear, P. G. 2004. Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol 6:401-10.
326. Spillmann, D. 2001. Heparan sulfate: anchor for viral intruders? Biochimie 83:811-7.
327. Stenlund, P., M. J. Lindberg, and L. A. Tibell. 2002. Structural requirements for high-affinity heparin binding: alanine scanning analysis of charged residues in the C-terminal domain of human extracellular superoxide dismutase. Biochemistry 41:3168-75.
328. Strom, M. B., B. E. Haug, O. Rekdal, M. L. Skar, W. Stensen, and J. S. Svendsen. 2002. Important structural features of 15-residue lactoferricin derivatives and methods for improvement of antimicrobial activity. Biochem Cell Biol 80:65-74.
329. Strom, M. B., O. Rekdal, W. Stensen, and J. S. Svendsen. 2001. Increased antibacterial activity of 15-residue murine lactoferricin derivatives. J Pept Res 57:127-39.
330. Strom, M. B., O. Rekdal, and J. S. Svendsen. 2000. Antibacterial activity of 15-residue lactoferricin derivatives. J Pept Res 56:265-74.
331. Strom, M. B., O. Rekdal, and J. S. Svendsen. 2002. The effects of charge and lipophilicity on the antibacterial activity of undecapeptides derived from bovine lactoferricin. J Pept Sci 8:36-43.
332. Subbalakshmi, C., and N. Sitaram. 1998. Mechanism of antimicrobial action of indolicidin. FEMS Microbiol Lett 160:91-6.
333. Superti, F., M. G. Ammendolia, P. Valenti, and L. Seganti. 1997. Antirotaviral activity of milk proteins: lactoferrin prevents rotavirus infection in the enterocyte-like cell line HT-29. Med Microbiol Immunol (Berl) 186:83-91.
334. Superti, F., R. Siciliano, B. Rega, F. Giansanti, P. Valenti, and G. Antonini. 2001. Involvement of bovine lactoferrin metal saturation, sialic acid and protein fragments in the inhibition of rotavirus infection. Biochim Biophys Acta 1528:107-15.
335. Suzuki, T., S. Futaki, M. Niwa, S. Tanaka, K. Ueda, and Y. Sugiura. 2002. Possible existence of common internalization mechanisms among argininerich peptides. J Biol Chem 277:2437-43.
336. Suzuki, Y. A., K. Shin, and B. Lonnerdal. 2001. Molecular cloning and functional expression of a human intestinal lactoferrin receptor. Biochemistry 40:15771-9.
337. Swart, P. J., M. E. Kuipers, C. Smit, R. Pauwels, M. P. deBethune, E. de Clercq, D. K. Meijer, and J. G. Huisman. 1996. Antiviral effects of milk proteins: acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro. AIDS Res Hum Retroviruses 12:769-75.
338. Tachezy, J., J. Kulda, I. Bahnikova, P. Suchan, J. Razga, and J. Schrevel. 1996. Tritrichomonas foetus: iron acquisition from lactoferrin and transferrin. Exp Parasitol 83:216-28.
339. Takakura, N., H. Wakabayashi, H. Ishibashi, K. Yamauchi, S. Teraguchi, Y. Tamura, H. Yamaguchi, and S. Abe. 2004. Effect of orally administered bovine lactoferrin on the immune response in the oral candidiasis murine model. J Med Microbiol 53:495-500.
340. Takase, K., K. Hagiwara, H. Onodera, Y. Nishizawa, M. Ugaki, T. Omura, S. Numata, K. Akutsu, H. Kumura, and K. Shimazaki. 2005. Constitutive expression of human lactoferrin and its N-lobe in rice plants to confer disease resistance. Biochem Cell Biol 83:239-49.
341. Takeshima, K., A. Chikushi, K. K. Lee, S. Yonehara, and K. Matsuzaki. 2003. Translocation of analogues of the antimicrobial peptides magainin and buforin across human cell membranes. J Biol Chem 278:1310-5.
342. Tamamura, H., T. Murakami, M. Masuda, A. Otaka, W. Takada, T. Ibuka, H. Nakashima, M. Waki, A. Matsumoto, N. Yamamoto, and et al. 1994. Structure-activity relationships of an anti-HIV peptide, T22. Biochem Biophys Res Commun 205:1729-35.
343. Tamamura, H., A. Otaka, T. Murakami, T. Ishihara, T. Ibuka, M. Waki, A. Matsumoto, N. Yamamoto, and N. Fujii. 1996. Interaction of an anti-HIV peptide, T22, with gp120 and CD4. Biochem Biophys Res Commun 219:555-9.
344. Tanaka, K., M. Ikeda, A. Nozaki, N. Kato, H. Tsuda, S. Saito, and H. Sekihara. 1999. Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. Jpn J Cancer Res 90:367-71.
345. Tanaka, T., S. Nakatani, X. Xuan, H. Kumura, I. Igarashi, and K. Shimazaki. 2003. Antiviral activity of lactoferrin against canine herpesvirus. Antiviral Res 60:193-9.
346. Tanaka, T., Y. Omata, A. Saito, K. Shimazaki, K. Yamauchi, M. Takase, K. Kawase, K. Igarashi, and N. Suzuki. 1995. Toxoplasma gondii: parasiticidal effects of bovine lactoferricin against parasites. Exp Parasitol 81:614-7.
347. Tani, F., K. Iio, H. Chiba, and M. Yoshikawa. 1990. Isolation and characterization of opioid antagonist peptides derived from human lactoferrin. Agric Biol Chem 54:1803-10.
348. Territo, M. C., T. Ganz, M. E. Selsted, and R. Lehrer. 1989. Monocytechemotactic activity of defensins from human neutrophils. J Clin Invest 84:2017-20.
349. Tinari, A., A. Pietrantoni, M. G. Ammendolia, P. Valenti, and F. Superti. 2005. Inhibitory activity of bovine lactoferrin against echovirus induced programmed cell death in vitro. Int J Antimicrob Agents 25:433-8.
350. Toka, F. N., C. D. Pack, and B. T. Rouse. 2004. Molecular adjuvants for mucosal immunity. Immunol Rev 199:100-12.
351. Tomita, M., W. Bellamy, M. Takase, K. Yamauchi, H. Wakabayashi, and K. Kawase. 1991. Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin. J Dairy Sci 74:4137-42.
352. Tomita, M., M. Takase, W. Bellamy, and S. Shimamura. 1994. A review:the active peptide of lactoferrin. Acta Paediatr Jpn 36:585-91.
353. Tomita, M., M. Takase, H. Wakabayashi, and W. Bellamy. 1994. Antimicrobial peptides of lactoferrin. Adv Exp Med Biol 357:209-18.
354. Tomita, M., H. Wakabayashi, K. Yamauchi, S. Teraguchi, and H. Hayasawa. 2002. Bovine lactoferrin and lactoferricin derived from milk:production and applications. Biochem Cell Biol 80:109-12.
355. Trybala, E., T. Bergstrom, B. Svennerholm, S. Jeansson, J. C. Glorioso, and S. Olofsson. 1994. Localization of a functional site on herpes simplex virus type 1 glycoprotein C involved in binding to cell surface heparan sulphate. J Gen Virol 75 (Pt 4):743-52.
356. Trybala, E., J. A. Liljeqvist, B. Svennerholm, and T. Bergstrom. 2000. Herpes simplex virus types 1 and 2 differ in their interaction with heparan sulfate. J Virol 74:9106-14.
357. Trybala, E., S. Olofsson, K. Mardberg, B. Svennerholm, K. Umemoto, J. C. Glorioso, and T. Bergstrom. 2004. Structural and functional features of the polycationic peptide required for inhibition of herpes simplex virus invasion of cells. Antiviral Res 62:125-34.
358. Trybala, E., A. Roth, M. Johansson, J. A. Liljeqvist, E. Rekabdar, O. Larm, and T. Bergstrom. 2002. Glycosaminoglycan-binding ability is a feature of wild-type strains of herpes simplex virus type 1. Virology 302:413-9.
359. Tryon, V. V., and J. B. Baseman. 1987. The acquisition of human lactoferrin by Mycoplasma pneumoniae. Microb Pathog 3:437-43.
360. Tsuda, H., K. Sekine, K. Fujita, and M. Ligo. 2002. Cancer prevention by bovine lactoferrin and underlying mechanisms--a review of experimental and clinical studies. Biochem Cell Biol 80:131-6.
361. Turchany, J. M., S. B. Aley, and F. D. Gillin. 1995. Giardicidal activity of lactoferrin and N-terminal peptides. Infect Immun 63:4550-2.
362. Ueta, E., T. Tanida, and T. Osaki. 2001. A novel bovine lactoferrin peptide, FKCRRWQWRM, suppresses Candida cell growth and activates neutrophils. J Pept Res 57:240-9.
363. Ulvatne, H., O. Samuelsen, H. H. Haukland, M. Kramer, and L. H. Vorland. 2004. Lactoferricin B inhibits bacterial macromolecular synthesis in Escherichia coli and Bacillus subtilis. FEMS Microbiol Lett 237:377-84.
364. Utsugi, T., A. J. Schroit, J. Connor, C. D. Bucana, and I. J. Fidler. 1991. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 51:3062-6.
365. Valenti, P., P. Visca, G. Antonini, and N. Orsi. 1985. Antifungal activity of ovotransferrin towards genus Candida. Mycopathologia 89:169-75.
366. van Berkel, P. H., M. E. Geerts, H. A. van Veen, M. Mericskay, H. A. de Boer, and J. H. Nuijens. 1997. N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA. Biochem J 328 (Pt 1):145-51.
367. van Berkel, P. H., M. M. Welling, M. Geerts, H. A. van Veen, B. Ravensbergen, M. Salaheddine, E. K. Pauwels, F. Pieper, J. H. Nuijens, and P. H. Nibbering. 2002. Large scale production of recombinant human lactoferrin in the milk of transgenic cows. Nat Biotechnol 20:484-7.
368. van der Kraan, M. I., J. Groenink, K. Nazmi, E. C. Veerman, J. G. Bolscher, and A. V. Nieuw Amerongen. 2004. Lactoferrampin: a novel antimicrobial peptide in the N1-domain of bovine lactoferrin. Peptides 25:177-83.
369. van der Kraan, M. I., K. Nazmi, A. Teeken, J. Groenink, W. van’t Hof, E. C. Veerman, J. G. Bolscher, and A. V. Nieuw Amerongen. 2005. Lactoferrampin, an antimicrobial peptide of bovine lactoferrin, exerts its candidacidal activity by a cluster of positively charged residues at the Cterminus in combination with a helix-facilitating N-terminal part. Biol Chem 386:137-42.
370. van der Kraan, M. I., J. van Marle, K. Nazmi, J. Groenink, W. van ‘t Hof, E. C. Veerman, J. G. Bolscher, and A. V. Nieuw Amerongen. 2005. Ultrastructural effects of antimicrobial peptides from bovine lactoferrin on the membranes of Candida albicans and Escherichia coli. Peptides 26:1537-42.
371. van der Strate, B. W., L. Beljaars, G. Molema, M. C. Harmsen, and D. K. Meijer. 2001. Antiviral activities of lactoferrin. Antiviral Res 52:225-39.
372. Veerman, E. C., K. Nazmi, W. Van’t Hof, J. G. Bolscher, A. L. Den Hertog, and A. V. Nieuw Amerongen. 2004. Reactive oxygen species play no role in the candidacidal activity of the salivary antimicrobial peptide histatin 5. Biochem J 381:447-52.
373. Viani, R. M., T. J. Gutteberg, J. L. Lathey, and S. A. Spector. 1999. Lactoferrin inhibits HIV-1 replication in vitro and exhibits synergy when combined with zidovudine. Aids 13:1273-4.
374. Viejo-Diaz, M., M. T. Andres, and J. F. Fierro. 2005. Different anti-Candida activities of two human lactoferrin-derived peptides, Lfpep and kaliocin-1. Antimicrob Agents Chemother 49:2583-8.
375. Viejo-Diaz, M., M. T. Andres, and J. F. Fierro. 2004. Modulation of in vitro fungicidal activity of human lactoferrin against Candida albicans by extracellular cation concentration and target cell metabolic activity. Antimicrob Agents Chemother 48:1242-8.
376. Vives, E., P. Brodin, and B. Lebleu. 1997. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272:16010-7.
377. Vives, R. R., A. Imberty, Q. J. Sattentau, and H. Lortat-Jacob. 2005. Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site. J Biol Chem 280:21353-7.
378. Vogel, H. J., D. J. Schibli, W. Jing, E. M. Lohmeier-Vogel, R. F. Epand, and R. M. Epand. 2002. Towards a structure-function analysis of bovine lactoferricin and related tryptophan- and arginine-containing peptides. Biochem Cell Biol 80:49-63.
379. Vogel, L., F. Geluk, H. Jansen, J. Dankert, and L. van Alphen. 1997. Human lactoferrin receptor activity in non-encapsulated Haemophilus influenzae. FEMS Microbiol Lett 156:165-70.
380. Vorland, L. H. 1999. Lactoferrin: a multifunctional glycoprotein. Apmis 107:971-81.
381. Vorland, L. H., H. Ulvatne, J. Andersen, H. Haukland, O. Rekdal, J. S. Svendsen, and T. J. Gutteberg. 1998. Lactoferricin of bovine origin is more active than lactoferricins of human, murine and caprine origin. Scand J Infect Dis 30:513-7.
382. Vorland, L. H., H. Ulvatne, O. Rekdal, and J. S. Svendsen. 1999. Initial binding sites of antimicrobial peptides in Staphylococcus aureus and Escherichia coli. Scand J Infect Dis 31:467-73.
383. Waarts, B. L., O. J. Aneke, J. M. Smit, K. Kimata, R. Bittman, D. K. Meijer, and J. Wilschut. 2005. Antiviral activity of human lactoferrin:inhibition of alphavirus interaction with heparan sulfate. Virology 333:284-92.
384. Wachinger, M., A. Kleinschmidt, D. Winder, N. von Pechmann, A. Ludvigsen, M. Neumann, R. Holle, B. Salmons, V. Erfle, and R. Brack-Werner. 1998. Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression. J Gen Virol 79 (Pt 4):731-40.
385. Wakabayashi, H., S. Abe, T. Okutomi, S. Tansho, K. Kawase, and H. Yamaguchi. 1996. Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents. Microbiol Immunol 40:821-5.
386. Wakabayashi, H., M. Kurokawa, K. Shin, S. Teraguchi, Y. Tamura, and K. Shiraki. 2004. Oral lactoferrin prevents body weight loss and increases cytokine responses during herpes simplex virus type 1 infection of mice. Biosci Biotechnol Biochem 68:537-44.
387. Wakabayashi, H., M. Takase, and M. Tomita. 2003. Lactoferricin derived from milk protein lactoferrin. Curr Pharm Des 9:1277-87.
388. Wang, Z., and G. Wang. 2004. APD: the Antimicrobial Peptide Database. Nucleic Acids Res 32:D590-2.
389. Ward, P. P., X. Zhou, and O. M. Conneely. 1996. Cooperative interactions between the amino- and carboxyl-terminal lobes contribute to the unique iron-binding stability of lactoferrin. J Biol Chem 271:12790-4.
390. Weinberg, E. D. 2001. Human lactoferrin: a novel therapeutic with broad spectrum potential. J Pharm Pharmacol 53:1303-10.
391. Weinberg, E. D. 2004. Suppression of bacterial biofilm formation by iron limitation. Med Hypotheses 63:863-5.
392. Weinberg, G. A. 1994. Iron chelators as therapeutic agents against Pneumocystis carinii. Antimicrob Agents Chemother 38:997-1003.
393. Weng, T. Y., L. C. Chen, H. W. Shyu, S. H. Chen, J. R. Wang, C. K. Yu, H. Y. Lei, and T. M. Yeh. 2005. Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells. Antiviral Res 67:31-7.
394. Williamson, P., and R. A. Schlegel. 1994. Back and forth: the regulation and function of transbilayer phospholipid movement in eukaryotic cells. Mol Membr Biol 11:199-216.
395. Wolf, J. S., D. Li, R. J. Taylor, and B. W. O’Malley, Jr. 2003. Lactoferrin inhibits growth of malignant tumors of the head and neck. ORL J Otorhinolaryngol Relat Spec 65:245-9.
396. Wu, H. F., D. M. Monroe, and F. C. Church. 1995. Characterization of the glycosaminoglycan-binding region of lactoferrin. Arch Biochem Biophys 317:85-92.
397. Wu, M., E. Maier, R. Benz, and R. E. W. Hancock. 1999. Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli. Biochemistry 38:7235-42.
398. WuDunn, D., and P. G. Spear. 1989. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J Virol 63:52-8.
399. Xia, G., J. Chen, V. Tiwari, W. Ju, J. P. Li, A. Malmstrom, D. Shukla, and J. Liu. 2002. Heparan sulfate 3-O-sulfotransferase isoform 5 generates both an antithrombin-binding site and an entry receptor for herpes simplex virus, type 1. J Biol Chem 277:37912-9.
400. Xu, Y. Y., Y. H. Samaranayake, L. P. Samaranayake, and H. Nikawa. 1999. In vitro susceptibility of Candida species to lactoferrin. Med Mycol 37:35-41.
401. Yalcin, A. S. 2006. Emerging therapeutic potential of whey proteins and peptides. Curr Pharm Des 12:1637-43.
402. Yamaguchi, H., S. Abe, and N. Takakura. 2004. Potential usefulness of bovine lactoferrrin for adjunctive immunotherapy for mucosal Candida infections. Biometals 17:245-8.
403. Yamaguchi, S., D. Huster, A. Waring, R. I. Lehrer, W. Kearney, B. F. Tack, and M. Hong. 2001. Orientation and dynamics of an antimicrobial peptide in the lipid bilayer by solid-state NMR spectroscopy. Biophys J 81:2203-14.
404. Yamauchi, K., M. Tomita, T. J. Giehl, and R. T. Ellison, 3rd. 1993. Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect Immun 61:719-28.
405. Yang, D., A. Biragyn, L. W. Kwak, and J. J. Oppenheim. 2002. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol 23:291-6.
406. Yang, L., T. A. Harroun, T. M. Weiss, L. Ding, and H. W. Huang. 2001. Barrel-Stave Model or Toroidal Model? A Case Study on Melittin Pores. Biophys. J. 81:1475-1485.
407. Yang, N., T. Lejon, and O. Rekdal. 2003. Antitumour activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin-derived peptide. J Pept Sci 9:300-11.
408. Yang, N., W. Stensen, J. S. Svendsen, and O. Rekdal. 2002. Enhanced antitumor activity and selectivity of lactoferrin-derived peptides. J Pept Res 60:187-97.
409. Yang, N., M. B. Strom, S. M. Mekonnen, J. S. Svendsen, and O. Rekdal. 2004. The effects of shortening lactoferrin derived peptides against tumour cells, bacteria and normal human cells. J Pept Sci 10:37-46.
410. Yasin, B., M. Pang, J. S. Turner, Y. Cho, N. N. Dinh, A. J. Waring, R. I. Lehrer, and E. A. Wagar. 2000. Evaluation of the inactivation of infectious Herpes simplex virus by host-defense peptides. Eur J Clin Microbiol Infect Dis 19:187-94.
411. Yasin, B., W. Wang, M. Pang, N. Cheshenko, T. Hong, A. J. Waring, B. C. Herold, E. A. Wagar, and R. I. Lehrer. 2004. Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J Virol 78:5147-56.
412. Yi, M., S. Kaneko, D. Y. Yu, and S. Murakami. 1997. Hepatitis C virus envelope proteins bind lactoferrin. J Virol 71:5997-6002.
413. Yoo, Y. C., R. Watanabe, Y. Koike, M. Mitobe, K. Shimazaki, S. Watanabe, and I. Azuma. 1997. Apoptosis in human leukemic cells induced by lactoferricin, a bovine milk protein-derived peptide: involvement of reactive oxygen species. Biochem Biophys Res Commun 237:624-8.
414. Yoo, Y. C., S. Watanabe, R. Watanabe, K. Hata, K. Shimazaki, and I. Azuma. 1998. Bovine lactoferrin and Lactoferricin inhibit tumor metastasis in mice. Adv Exp Med Biol 443:285-91.
415. Yoo, Y. C., S. Watanabe, R. Watanabe, K. Hata, K. Shimazaki, and I. Azuma. 1997. Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn J Cancer Res 88:184-90.
416. Yoon, C. S., K. D. Kim, S. N. Park, and S. W. Cheong. 2001. alpha(6) Integrin is the main receptor of human papillomavirus type 16 VLP. Biochem Biophys Res Commun 283:668-73.
417. Zasloff, M. 1987. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci U S A 84:5449-53.
418. Zautner, A. E., U. Korner, A. Henke, C. Badorff, and M. Schmidtke. 2003. Heparan sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackievirus B3 PD infection. J Virol 77:10071-7.
419. Zelezetsky, I., U. Pag, H. G. Sahl, and A. Tossi. 2005. Tuning the biological properties of amphipathic alpha-helical antimicrobial peptides: rational use of minimal amino acid substitutions. Peptides 26:2368-76.
420. Zhang, L., and T. J. Falla. 2006. Antimicrobial Peptides - therapeutic potential Expert Opin Pharmacother 7:653-63.
421. Zhang, L., A. Rozek, and R. E. W. Hancock. 2001. Interaction of cationic antimicrobial peptides with model membranes. J Biol Chem 276:35714-22.
422. Ziere, G. J., M. C. van Dijk, M. K. Bijsterbosch, and T. J. van Berkel. 1992. Lactoferrin uptake by the rat liver. Characterization of the recognition site and effect of selective modification of arginine residues. J Biol Chem 267:11229-35.
423. Zioudrou, C., R. A. Streaty, and W. A. Klee. 1979. Opioid peptides derived from food proteins. The exorphins. J Biol Chem 254:2446-9.
424. Zuccotti, G. V., F. Salvini, E. Riva, and C. Agostoni. 2006. Oral lactoferrin in HIV-1 vertically infected children: an observational follow-up of plasma viral load and immune parameters. J Int Med Res 34:88-94.
425. Zwaal, R. F., and A. J. Schroit. 1997. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 89:1121-32.